课题基金 / 基金详情

Iron catalysed, site-selective functionalisation reactions: Cutting edge analysis for state-of-the-art synthesis

Iron catalysed, site-selective functionalisation reactions: Cutting edge analysis for state-of-the-art synthesis
铁催化的位点选择性官能化反应:最先进合成的前沿分析
批准号:
2751981
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2022
资助国家:
英国
项目状态:
未结题
起止时间:
2022 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
手性氢氟化分子是重要的活性药物成分,对19F放射性标记和正电子发射断层扫描(PET)等医学成像的应用至关重要。对化学家来说,实现氢氟化和在未活化的烯烃上安装慈善机构仍然是一个挑战。目的实现非活化烯烃的对映选择性加氢氟化目的建立非活化烯烃的区域选择性加氢氟化区域选择性制备增值氟化分子利用氘取代化合物发展手性质谱法发展表征监测和量化反应研究的潜在应用在药物基序合成中的应用在医学成像中的应用在氟放射性标记中的应用研究的好处扩大了化学家获得区域选择性和对映选择性氟化和氘化的范围开发了质谱分析方法来监测和量化对映选择性反应与资助者的目标相关这个项目与优先事项一致EPSRC致力于发展英国物理科学领域的人力资本,通过科学创新造福社会和人类。该项目符合GSK在药物设计和交付方面不断创新的业务重点。Kathryn Proctor博士是MC2的质谱专家。她将监督和监督外消旋物和区域选择性氟化化合物的质谱分析。广泛的活动不限于方法开发,一对一的仪器培训,数据分析和反应条件筛选是她将作为联合主管为该项目做出的一些技术贡献。
英文摘要
Chiral hydrofluorinated molecules are important active pharmaceutical ingredients, crucial for 19F radiolabelling and application in medical imaging such as Positron Emission Tomography (PET). Achieving hydrofluorination and installing charity on unactivated alkenes remains a challenge to chemists.AimTo achieve enantioselective hydrofluorination of unactivated alkenesOBJECTIVESDevelop a regioselective hydrofluorination of unactivated alkenesRegioselective preparation of value-added fluorinated moleculesDevelop chiral-by-virtue of deuterium-substituted compoundsMass spectrometry method development to characterise, monitor and quantify the reactionsPotential application of researchApplication in the synthesis of drug motifApplication in medical imagingApplication in radiolabelling with Fluorine-19Benefit of research Expanding the scope available to chemists to access regioselective and enantioselective fluorination and deuterationDeveloping analytical methods with mass spectrometry to monitor and quantify enantioselective reactionsRelevance to goals of the fundersThis project aligns with the priorities of EPSRC of developing human capital in the physical sciences in the UK to benefit society and, mankind through scientific innovation.This project aligns with the business priorities of GSK of continuous innovation in drug design and delivery.Role of the second supervisor (Dr Kathryn Proctor)Dr Kathryn Proctor is an expert mass spectrometrist at MC2. She will oversee and supervise the analysis of the racemate and regioselective fluorinated compounds using mass spectrometry. A wide range of activities not limited to method development, one-on-one training on instrumentation, data analysis, and reaction condition screening are some of the technical contributions she will make to this project as a co-supervisor.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金